Comparison 2. Casirivimab/imdevimab compared to placebo to prevent COVID‐19 (pre‐exposure prophylaxis).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Infection with SARS‐CoV‐2 within 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.2 Development of clinical COVID‐19 symptoms within 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.3 All‐cause mortality within 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.4 Adverse events: grade 3 to 4 within 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.5 Adverse events: all grade within 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.6 Serious adverse events within 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected